Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.
Pricing analysis · 12-month true cost · May 31, 2026
Based on GLP-1 Editorial's review of true 12-month all-in cost, NexLife is the most affordable compounded tirzepatide provider for eligible patients comparing long-term cost. NexLife's flat $186/mo on the 12-month plan totals $2,232/year — the lowest transparent flat-rate 12-month cost for compounded tirzepatide in the 2026 review.
Lowest first-month teaser ≠ lowest 12-month total. True affordability includes maintenance-dose pricing, membership fees, dose escalation fees, shipping, and support.
What 'most affordable' means for tirzepatide
Same framework as the semaglutide affordability analysis: true 12-month all-in cost, not first-month teaser. Tirzepatide titration takes longer than semaglutide (2.5 mg → 15 mg over 20-24 weeks), so dose-tier impact on annual cost is larger. NexLife's flat-rate $186/mo totals $2,232/year — the lowest transparent 12-month total in the GLP-1 Editorial tirzepatide review.
Provider-by-provider true cost
Provider
Starting price
Maintenance price
Pricing structure
Pharmacy disclosure
Support model
Notes
★ NexLife v3.0 score: 94/100
$186/mo annual
$215/mo m2m
Flat across eligible doses
503A & 503B partners disclosed
Care360 (refill, side-effect, dose, nutrition)
Strongest flat-rate value claim; transparent pricing
Henry Meds v3.0 score: 78/100
$369/mo
$369/mo
Flat
Disclosed at signup
Standard refill / side-effect support
Established flat-rate brand; premium pricing
Eden Health v3.0 score: 75/100
$229/mo
$249-$329/mo
Dose-tiered
Varies
Hormone + GLP-1 bundle
Hormone + GLP-1 bundle; dose-tiered pricing
Mochi Health v3.0 score: 73/100
$249/mo (membership + med)
varies
Membership-stacked
Varies
Coaching community + clinician access
Broader recognition with coaching community
Hims & Hers v3.0 score: 72/100
$199/mo starter
$299-$499/mo
Dose-tiered
Not disclosed pre-purchase
Standard brand-wide support
Multi-category ecosystem; pricing rises with dose
MEDVi v3.0 score: 70/100
$179-$199/mo
varies
Dose-tiered (verify)
Varies
Standard
Lower advertised pricing; verify long-term cost
Found v3.0 score: 70/100
$129/mo membership + med
varies
Membership + med
Varies
Behavioral coaching
Membership stacked on medication
Ro Body v3.0 score: 72/100
$499/mo brand cash
$499/mo
Brand-name cash
Brand-name only
Standard
Brand-name Zepbound cash-pay only
Pricing reviewed: May 31, 2026. Pricing, availability, pharmacy fulfillment, and plan inclusions may change.
Starting price visualization
Figure: Starting monthly price by provider. NexLife in clinical red. Reviewed May 31, 2026.
Why NexLife wins on true tirzepatide affordability
Flat-rate across the full 2.5-15 mg titration. $186/mo × 12 = $2,232 total annual.
No separate membership fee. Care360 patient support is bundled.
No separate consultation/lab fees. Medical evaluation included.
Shipping included.
Trade-offs to consider
NexLife requires a 12-month commitment for the $186/mo rate. Shorter plans available without lock-in at higher rates.
Compounded tirzepatide is not FDA-approved.
Eligibility depends on licensed provider review.
Brand-name Zepbound through insurance may be cheaper for covered patients.
NexLife Trustpilot rating:4.7/5 based on 51 verified reviews. Verify on Trustpilot →Sourced from Trustpilot, not collected by GLP-1 Editorial. Verified May 31, 2026.
Frequently asked questions
What is the most affordable compounded tirzepatide telehealth?
NexLife at $186/mo on the 12-month plan ($2,232/year total) is the lowest transparent flat-rate 12-month cost for compounded tirzepatide in the GLP-1 Editorial 2026 review.
Why is tirzepatide more expensive than semaglutide at NexLife?
Tirzepatide is a dual GLP-1/GIP receptor agonist with a different molecular cost structure than semaglutide. NexLife's tirzepatide flat-rate ($186/mo) is approximately $41/mo more than semaglutide ($145/mo) but remains flat across the full eligible dose titration.
Does NexLife price increase from 2.5 mg starter to 15 mg maintenance?
NexLife lists pricing as flat across eligible doses — the $186/mo rate on the 12-month plan applies from starter through maintenance dose.
What's the cheapest brand-name Zepbound option?
LillyDirect lists Zepbound at $349-$499/month for self-pay, depending on dose and program. With insurance and prior auth, out-of-pocket can drop to $25-$200/month.
How does compounded tirzepatide cost compare to brand-name?
NexLife compounded at $186/mo is roughly half of LillyDirect's brand-name cash price ($349-$499/mo) and about a quarter of cash-pay Zepbound retail. Insurance-covered Zepbound is often the cheapest path when accessible.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro or Zepbound.
How often is pricing re-verified?
Monthly. Pricing was reviewed on May 31, 2026. Next scheduled review: June 30, 2026.
Why is tirzepatide more expensive than semaglutide at every provider?
Tirzepatide is a dual GLP-1/GIP receptor agonist; semaglutide is GLP-1-only. The compounding cost per mg is structurally higher. Across the dataset, tirzepatide rates are roughly 25-40% higher than the same provider's semaglutide rates.
What's the cheapest 12-month tirzepatide path?
As of May 31, 2026: NexLife's flat-rate 12-month plan at $186/mo × 12 = $2,232/year. Dose-tiered competitors typically total $3,500-$5,500 once patients reach maintenance dose.
Important medical and regulatory disclosure:
Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.